Notwithstanding positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from PBMs. Such companies are often erecting barriers to access, including significant price restrictions and PA that limit patient access. Analysts believe that such cover… Read More